COMPARATIVE STUDY OF TELMISARTAN WITH PIOGLITAZONE ON INSULIN RESISTANCE IN TYPE 2 DIABETIC MICE
Telmisartan With Pioglitazone on Insulin Resistance in Type 2 Diabetes
Keywords:Diabetes mellitus, Peroxisome proliferator activated receptor gamma (PPAR gamma), Pioglitazone, Telmisartan, Renin angiotensin system (RAS)
Objective: To evaluate and compare the effects of telmisartan and pioglitazone on peripheral insulin resistance in diabetic mice.
Study Design: Randomized control trail.
Place and Duration of Study: National Institute of Health, Islamabad and pharmacology dept, Army Medical College, from 17th March to 17th June 2014.
Material and Methods: Twenty four BALB/c mice, both male and female, of 35 to 40 grams were used for this study. Animals were randomly divided into four groups. Two were taken as control groups, one was normal control and the other was diabetic control. Two were taken as interventional groups and received either pioglitazone or telmisartanfor four weeks after induction of diabetes.
Results: After treatment, pioglitazone reduced all the biochemical parameters significantly when compared with diabetic control. Negative correlation between glucose and insulin was changed into positive correlation (r-value, 0.92) with significant p-value (0.015) in pioglitazone treated group, while telmisartan only managed to convert a negative correlation between insulin and glucose into statistically non-significant positive.
Conclusion: Telmisartan although reduces glucose levels and improves beta cell mass but the effect is statistically non-significant as compared to pioglitazone. In hypertensive type 2 diabetics a combination of these two drugs may help in reducing the dose of pioglitazone and consequently the cardiovascular adverse effects of pioglitazone.